Sinopharm Accord (SZ000028), full name Sinopharm Accord Pharmaceutical Co., Ltd. . The controlling shareholder is Sinopharm Holdings Co., Ltd. , and the actual controller is China National Pharmaceutical Group Co., Ltd. . The company’s main business includes pharmaceutical distribution and pharmaceutical retail. In the field of pharmaceutical distribution, the company continuously integrates distribution and logistics businesses, deeply penetrates the terminal market, improves the stepped distribution network, and builds a smart supply chain, and is committed to becoming the most influential in southern China. Strong, the highest share, the most complete variety, the best service, and the fastest delivery of medical and health products and service providers. In the field of pharmaceutical retail, the company's National University Pharmacy is a pharmaceutical retail company with a leading sales scale in the country, and one of the few domestic companies that have a national direct pharmaceutical retail network.
The company’s pharmaceutical distribution business is mainly based in Guangdong and Guangxi. As of June 30, 2021, there are 1061 secondary and tertiary medical institutions in operation in 2021; 6564 primary-level medical customers in operation; retail end customers in operation (chain drugstores) , Single stores, and hospital self-financed pharmacies) 4947, and the pharmaceutical distribution business has achieved the largest scale in Guangdong and Guangxi.
In terms of pharmaceutical retail, as of June 30, 2021, the National University Pharmacy has 8439 stores, covering 20 provinces, autonomous regions, and municipalities across the country, and entering nearly 155 large and medium-sized cities, forming coverage in Northeast, East, North, and South China The network of pharmacies in coastal urban agglomerations has gradually spread into the northwest, central plains and inland urban agglomerations.
Sinopharm Accord has a strong network coverage and layout. Relying on a comprehensive network and rich variety resources, based on the integration of wholesale and retail, Sinopharm Accord has a complete pharmaceutical distribution network in the Guangdong and Guangxi regions, and sales in various formats have grown steadily over the years. In the national retail network layout, the scale continues to lead.
Secondly, a complete logistics distribution system has been established. Sinopharm’s distribution system adopts supply chain management and warehouse management solution systems.It has 5 large-scale automated logistics centers and 15 regional distribution centers, including Guangzhou, Shenzhen, Foshan, Nanning, and Liuzhou, forming a stepped logistics distribution network. It is the first to obtain third-party logistics qualifications in Guangdong and Guangxi. It has the largest network in southern China. The widest and most comprehensive professional medical logistics capabilities.
The company's operating performance reached a new high in 2020. The company completed a total of 59.649 billion yuan in operating income throughout the year, an increase of 13.00% year-on-year; operating profit was 2.164 billion yuan, an increase of 18.21% year-on-year; net profit was 1.721 billion yuan, an increase of 16.29% year-on-year; attribution The net profit of shareholders of listed companies was 1.402 billion yuan, a year-on-year increase of 10.57%.
In the first half of 2021, the company's performance still achieved good performance. The accumulated operating income was 33.163 billion yuan, a year-on-year increase of 22.06%; operating profit was 1.137 billion yuan, a year-on-year increase of 12.13%; net profit was 908 million yuan, a year-on-year increase of 12.62%; attribution The net profit of shareholders of listed companies was 741 million yuan, a year-on-year increase of 15.23%.
K-line chart of company stock price
Disclaimer: All data and information in this article are derived from public information such as the company's annual report and financial websites. Anything mentioned in this article is not a basis for investment transactions and does not constitute Any investment advice! Do not assume any responsibility for the losses caused by the use of the content of this article!
.-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-